Children’s Colorado will offer the COVID-19 vaccine to patients ages 16 and older beginning Friday, April 2. Find updates on vaccine clinics at Children's Colorado. Patients with a MyChart account will receive updates (by email and in the app) regarding the vaccine as they become eligible.
A small number of pregnant women carry the Sjogren's antibody, and their growing baby can develop a cardiac complication called CAVB.
There is a short window of time where CAVB hasn't fully developed and is treatable, but without constant heart monitoring, it's difficult to successfully intervene.
Moms in this study were given heart monitors to use at home, and they felt comfortable and empowered doing so.
For health professionals
Pregnant women carrying Sjogren's antibody are at risk for their fetuses developing CAVB.
Our researchers were among the first to give mothers commercial Doppler heart monitors to use twice a day to detect emergent CAVB.
Study participants reported decreased stress and researchers found equipping mothers with a Doppler was a reasonable medical approach.
About 3% of all pregnant women carry an antibody called anti-SSA, or Sjogren’s antibody, which can be detected by a simple blood test. In 4% of pregnancies, maternal anti-SSA antibodies cross the placenta at 18 weeks and cause inflammation and fibrosis of the fetal conduction system, resulting in complete atrioventricular block (CAVB) by 25 weeks. Once established, CAVB is irreversible and either death or lifelong cardiac pacing is inevitable.
However, if "emergent" CAVB – the time of irregular rhythm when the fetal heart is transitioning from normal rhythm to CAVB – is detected – transplacental treatment can restore sinus rhythm. To date, surveillance for emergent CAVB has been with weekly fetal echocardiograms, but since emergent CAVB develops in 24 hours, this technique has rarely been successful. An important barrier to progress in this field is the lack of a surveillance method to detect emergent CAVB and prevent progression to irreversible CAVB. Continuous fetal monitoring from 18 to 25 weeks would be the true "gold standard" to detect this fleeting period of emergent CAVB, but this is unrealistic.
Study authors proposed pregnant anti-SSA positive mothers use a commercially available Doppler fetal heart rate monitor* two times per day to detect the irregular rhythm of emergent CAVB ("home monitoring"). All mothers will also undergo standard of care fetal echo surveillance ("office monitoring") and the two monitoring methods will be compared in the successful detection of emergent CAVB. The multicenter** international observational study, which is still ongoing, is led by Bettina Cuneo, MD, Director of Fetal Cardiology at the Colorado Fetal Care Center and Professor of Pediatrics and Obstetrics at the University of Colorado School of Medicine.
Pregnant anti-SSA positive mothers are recruited at 16 to 18 weeks of gestation and taught how to use the Doppler fetal heart rate monitor. The mothers are asked to monitor two times per day and to contact their provider if the rhythm is irregular or they cannot hear the baby's heartbeat. They are seen every other week until 25 weeks of gestation, after which they continue with normal obstetrical care. Participants are also assessed for stress, anxiety and satisfaction with the monitoring.
Decision tree for maternal home FHR Doppler monitoring
* The Cole family provided funding for the monitors in memory of their daughter, Rachel.
** Participating centers include: Sick Kids Hospital, Toronto, Ontario, Canada; Stollery Children's Hospital, Alberta, Canada; Karolinska University, Stockholm, Sweden; Children's Hospital Philadelphia; The University of California-San Francisco; Children's National Hospital, Washington DC; Morgan Stanley Hospital, Columbia, New York; Sanford Health Systems, Fargo, North Dakota
4%Of affected fetuses with anti-SSA develop CAVB
FIRSTStudy to use commercial Dopplers for medical indications
31%Of affected fetuses die in-utero or in first year of life
In a pilot study, two mothers with normal office monitoring detected the irregular rhythm of emergent CAVB during home monitoring, which was not detected by echo surveillance. In both fetuses, emergent CAVB developed in less than 24 hours. As part of a larger study, home fetal heart rate monitoring was found to be feasible and empowering to mothers.
One hundred and twenty-five of the 133 (94%) recruited anti-SSA positive mothers were enrolled and 120 (96%) completed the study. No emergent CAVB or CAVB was missed and all babies were born in sinus rhythm. There was a high rate of acceptance and satisfaction and there was decreased stress with monitoring among the participants. All said they would monitor again in subsequent pregnancies.
Researchers concluded that it is feasible to use a commercially available Doppler monitor to detect arrhythmias and it does not increase stress for participating women. While commercial Dopplers have been available for many years, study authors have found no other instances where they have been used solely for medical indications.
Cuneo BF, Ambrose SE, Tworetzky W. Detection and successful treatment of emergent anti-SSA-mediated fetal atrioventricular block. Am J Obstet Gynecol. 2016;215(4):527-8.
Children's Hospital Colorado partners with NRC Health to gather star ratings and reviews from patients, residents and family survey data.
This provider either practices in a department or specialty that we currently do not survey, or does not have at least 10 ratings in the last 12 months. Learn more about patient ratings and reviews.
Children's Hospital Colorado providers
Children’s Hospital Colorado providers are faculty members of the University of Colorado School of Medicine. Our specialists are nationally ranked and globally recognized for delivering the best possible care in pediatrics.
Some healthcare professionals listed on our website have medical privileges to practice at Children’s Hospital Colorado, but they are community providers. They schedule and bill separately for their services, and are not employees of the Hospital.